Nepal support for
Inactivated Polio Vaccine (IPV)

This decision letter sets out the Programme Terms of a Programme.

1. Country: Nepal
2. Grant number: 1418-NPL-25c-X
3. Date of decision letter: 12 February 2016 (replaces the previous decision letter for IPV issued on 27 April 2015)
4. Date of the partnership framework agreement: 22 August 2014
5. Programme title: NVS, IPV routine
6. Vaccine type: Inactivated Polio Vaccine (IPV)
7. Requested product presentation and formulation of vaccine: Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID
9. Programme budget (indicative) (subject to the terms of the partnership framework agreement):
   Please note that endorsed or approved amounts for 2017 and 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>Total³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>437,731</td>
<td>2,575,500</td>
<td>502,500</td>
<td>3,515,731</td>
</tr>
</tbody>
</table>

10. Vaccine Introduction Grant: Not applicable
11. Indicative Annual Amounts (subject to the terms of the partnership framework agreement):²

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IPV vaccines doses</td>
<td>2,486,700</td>
<td>535,400</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>1,604,400</td>
<td>426,800</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>17,650</td>
<td>4,700</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>2,575,500</td>
<td>502,500</td>
</tr>
</tbody>
</table>

12. Procurement agency: UNICEF

¹ Please refer to section 18 for additional information on IPV presentation.
² This is the entire duration of the programme.
³ This is the total amount endorsed by Gavi for 2015 to 2017.
⁴ The Vaccine Introduction Grant was disbursed on 25 July 2014 and no further funding has been approved.
⁵ This is the amount that Gavi has approved. The Annual Amount for 2016 has been amended.
13. **Self-procurement**: Not applicable

14. **Co-financing obligations**: Not applicable
   Gavi’s usual co-financing requirements do not apply to IPV. However, Nepal is encouraged to contribute to vaccine and/or supply costs for IPV.

15. **Operational support for campaigns**: Not applicable

16. **Additional reporting requirements**: Nepal shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

<table>
<thead>
<tr>
<th>Reports, documents and other deliverables</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Progress Report or equivalent</td>
<td>15 May 2016</td>
</tr>
</tbody>
</table>

17. **Financial clarifications**: Nepal shall provide the following clarifications to Gavi*: Not applicable
   
   *Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements

18. **Other conditions**: If Nepal envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in the initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Nepal.

Signed by,

On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
12 February 2016